Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149 Münster, Germany.
Max Planck Institute for Molecular Biomedicine, 48149 Münster, Germany.
Stem Cell Reports. 2021 Apr 13;16(4):771-783. doi: 10.1016/j.stemcr.2021.03.001. Epub 2021 Mar 25.
Limited access to human oligodendrocytes impairs better understanding of oligodendrocyte pathology in myelin diseases. Here, we describe a method to robustly convert human fibroblasts directly into oligodendrocyte-like cells (dc-hiOLs), which allows evaluation of remyelination-promoting compounds and disease modeling. Ectopic expression of SOX10, OLIG2, and NKX6.2 in human fibroblasts results in rapid generation of O4 cells, which further differentiate into MBP mature oligodendrocyte-like cells within 16 days. dc-hiOLs undergo chromatin remodeling to express oligodendrocyte markers, ensheath axons, and nanofibers in vitro, respond to promyelination compound treatment, and recapitulate in vitro oligodendroglial pathologies associated with Pelizaeus-Merzbacher leukodystrophy related to PLP1 mutations. Furthermore, DNA methylome analysis provides evidence that the CpG methylation pattern significantly differs between dc-hiOLs derived from fibroblasts of young and old donors, indicating the maintenance of the source cells' "age." In summary, dc-hiOLs represent a reproducible technology that could contribute to personalized medicine in the field of myelin diseases.
人类少突胶质细胞获取途径有限,这阻碍了我们对髓鞘疾病中少突胶质细胞病理的更好理解。在这里,我们描述了一种将人类成纤维细胞直接转化为少突胶质样细胞(dc-hiOL)的方法,该方法可用于评估促髓鞘再生化合物和疾病建模。在人类成纤维细胞中异位表达 SOX10、OLIG2 和 NKX6.2 可快速生成 O4 细胞,这些细胞在 16 天内进一步分化为 MBP 成熟的少突胶质样细胞。dc-hiOL 经历染色质重塑以表达少突胶质细胞标志物,在体外包绕轴突并形成纳米纤维,对促髓鞘形成化合物治疗有反应,并在体外再现与 PLP1 突变相关的 Pelizaeus-Merzbacher 脑白质营养不良相关的少突胶质细胞病变。此外,DNA 甲基组分析提供的证据表明,源自年轻和老年供体成纤维细胞的 dc-hiOL 之间的 CpG 甲基化模式存在显著差异,这表明维持了源细胞的“年龄”。总之,dc-hiOL 代表了一种可重复的技术,可有助于髓鞘疾病领域的个性化医疗。